SERB has a full range of internal research capabilities.  Our clinical, regulatory, and quality teams work together to manage a robust pipeline of projects addressing high unmet medical needs in critical care and rare diseases.

We conduct research internally and through partnership with third-party research providers and independent investigators.  These projects include:

• Developing new innovative products, such as new biologic antidotes that leverage our polyclonal antibody platform
• Supporting independent research in the form of Investigator Initiated Studies (IIS) that further the understanding of diseases and the role our therapies can play in treatment
• Incremental innovation to expand the usefulness of our products, such as registering products in a new geography or label extensions to address new indications
• Working with partners to bring new products to market or to support marketing authorisations in new territories